"Moderna's Surprising Quarterly Profit Signals Shift Away from Covid"
TL;DR Summary
Moderna's stock jumped 9.5% after announcing a surprise profit of $217 million in Q4, beating analysts' estimates. The company's Q4 revenue of $2.8 billion, primarily from international sales of its Spikevax COVID-19 vaccine, also exceeded expectations. While risk-averse investors may prefer other stocks, aggressive investors could find Moderna appealing, especially with potential upcoming regulatory approvals for its RSV and seasonal flu vaccines.
- Why Moderna Stock Is Jumping Today The Motley Fool
- Moderna stock jumps after company posts surprise quarterly profit even as Covid vaccine sales plunge CNBC
- Moderna Is Pivoting From Covid—the Results Are on Their Way The Wall Street Journal
- Investors hone in on Moderna's RSV, CMV prospects after 'transition' year Fierce Biotech
- Moderna rises on Q4 results: Focus on the pipeline, analyst says Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
1 min
vs 2 min read
Condensed
81%
325 → 62 words
Want the full story? Read the original article
Read on The Motley Fool